Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Co-Director, Melanoma Research Program
Professor of Medicine, NYU Grossman School of Medicine
New York, NY
This enduring TeleECHO program will explore key clinical practice insights for management of patients with BRAF-mutated metastatic melanoma. Over the course of this activity there will be discussion of the clinical profiles of frontline combination immuno- and targeted treatment options in BRAF-mutated metastatic melanoma as well as emerging data from clinical trials and real-world studies examining sequencing of these therapies. Interactive case studies will illustrate strategies for treatment selection, mitigation of adverse events, and management considerations for patients with BRAF-mutated metastatic melanoma.
This activity is intended for community-based medical oncologists, and other allied healthcare practitioners involved in the management and treatment of patients with metastatic melanoma.
Upon the completion of this program, attendees should be able to:
- Assess the clinical profiles of frontline combination immuno- and targeted treatment options used for the management of BRAF-mutated metastatic melanoma
- Evaluate data from clinical trials and real-world studies examining the effects of sequencing frontline combination immuno- and targeted treatment options for the management of BRAF-mutant metastatic melanoma
- Identify the AEs associated with frontline combination immuno- and targeted treatment options for BRAF-mutated metastatic melanoma in order to mitigate them should they arise
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with melanoma.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Weber receives consulting fees from Merck, Genentech, Astra Zeneca, Pfizer, Regeneron, GSK, Alkermes, Novartis, Celldex, Incyte, and EMD Serono, and serves on advisory boards for Bristol Myers Squibb; he holds equity in Instil Bio, Biond, OncoC4, and Evaxion. He serves on scientific advisory boards for OncoC4, Instil Bio, Incyte, Biond, Neximmune, ImCheck and Sellas. Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker and a TIL growth method that Dr. Weber is named on, as well as on a PD-1 biomarker patent by Biodesix.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.